3,098 Shares in Solventum Co. (NYSE:SOLV) Bought by Petros Family Wealth LLC

Petros Family Wealth LLC bought a new position in shares of Solventum Co. (NYSE:SOLV) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 3,098 shares of the company’s stock, valued at approximately $205,000.

A number of other hedge funds have also made changes to their positions in SOLV. Sterling Capital Management LLC lifted its stake in Solventum by 52.6% in the 4th quarter. Sterling Capital Management LLC now owns 8,507 shares of the company’s stock valued at $562,000 after buying an additional 2,932 shares in the last quarter. Treasurer of the State of North Carolina lifted its position in shares of Solventum by 0.6% in the fourth quarter. Treasurer of the State of North Carolina now owns 60,952 shares of the company’s stock valued at $4,026,000 after acquiring an additional 380 shares in the last quarter. APG Asset Management US Inc. acquired a new stake in shares of Solventum during the fourth quarter valued at $200,000. Raymond James Financial Inc. purchased a new stake in Solventum during the 4th quarter worth about $18,583,000. Finally, APG Asset Management N.V. acquired a new position in Solventum in the 4th quarter valued at about $546,000.

Wall Street Analyst Weigh In

SOLV has been the topic of several recent analyst reports. The Goldman Sachs Group upped their price objective on shares of Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a research note on Monday, March 3rd. Mizuho increased their price target on Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a research note on Monday, March 3rd. Wells Fargo & Company lifted their price objective on Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a research report on Friday, February 28th. Piper Sandler increased their target price on Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research report on Friday, February 28th. Finally, Morgan Stanley upped their price objective on shares of Solventum from $73.00 to $80.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 5th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, Solventum presently has an average rating of “Hold” and an average target price of $79.86.

Solventum Stock Performance

NYSE SOLV opened at $66.19 on Friday. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $85.92. The firm has a market capitalization of $11.45 billion and a P/E ratio of 24.07. The business’s 50-day simple moving average is $74.19 and its 200-day simple moving average is $71.70.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.